An Investigational Drug (TPST-1495) in Patients With Familial Adenomatous Polyposis

An Investigational Drug (TPST-1495) in Patients With Familial Adenomatous Polyposis is a phase 2, interventional study registered as NCT06557733 by National Cancer Institute (NCI), with a registry enrolment figure of 38 participants, started 2026-03-31 and due to reach its primary completion in 2027-06-30. Interventions recorded: Biopsy Procedure; Biospecimen Collection; EP2/EP4 Antagonist TPST-1495; Esophagogastroduodenoscopy; Gastrointestinal Endoscopy; Questionnaire Administration. Conditions listed: Colorectal Carcinoma; Familial Adenomatous Polyposis. Primary outcome: Percent change in duodenal polyp burden; Incidence of adverse events. Colorectal eligibility wording from the registry: "* Clinical diagnosis of classic FAP with ≥ 100 colorectal adenomas status post colectomy or a sub-total colectomy and a family history of FAP". Sites: United States. No results are recorded here; the registry entry is the source.